Sanofi Consumer Health Care India Ltd, the pharmaceutical company that makes Combiflam among other consumer drugs, announced to sell 26% of its equity shares to Opal Bidco SAS along with U.S.-based ...

Viking Therapeutics plans to advance its obesity drug VK2735 to Phase III trials by late 2024, following Phase II results ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

The focal points of the events were artificial intelligence and global market developments and innovations for air cargo and ...

The Competition Commission of Pakistan (CCP) on Friday approved the acquisition of trademarks for the pharmaceutical product ...

Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.

In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves ...

Pullman & Comley and Day Pitney welcome experienced attorneys to their teams; Lawyers for Good Government announces award ...

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance ...

Sanofi agrees to sell a 50% stake in Opella to CDR for €15bn, securing job promises. Discover the impact on France ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sanofi (SNYNF – Research Report) and ...

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant ...